For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit


Myeloid (My Heme Panel) is a next generation sequencing (NGS) test which interrogates mutation status of recurrently mutated genes that play an important role in the diagnosis, prognosis and clinical management of patients with myeloid neoplasms, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), and MDS/MPN.  In addition, with the emergent clinical relevance of clonal cytopenia of undermined significance (CCUS), this NGS panel serves as a useful ancillary test in the initial evaluation of patients with cytopenia. This assay provides clinically relevant, myeloid-related molecular profiles from hematologic samples of patients in a timely and accurate fashion for the clinicians and pathologists.  Results generated from this assay can be integrated into routine clinical practice. 

Myeloid Fact Sheet

Specimen Requirements:

  • A minimum of 1 ml of fresh peripheral blood or bone marrow aspirates collected in EDTA (lavender top) tubes
  • At least 20 million cells of mononuclear cells isolated (fresh or frozen)
  • At least 1 μg of DNA

Ordering the Test

Please discuss with your oncologist whether ordering this test is right for you. The Myeloid Mutation Panel is available in Epic and can be found within the Immunopathology Molecular Order. An immunopathologist can also order the test directly through CoPath.


My Heme Panel was developed and its performance was determined by the Molecular Hematopathology Laboratory at Weill Cornell Medicine. This method has not been cleared by the Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.

Absence of detection of a genetic alteration by this assay implies that it is not identified within the detection limit of the assay, and does not necessarily rule out its absence in the specimen. Variants of low frequency, for example, subclonal mutations, may escape detection in this assay when the coverage depth is relatively low.

High prevalence germline alterations (e.g, germline polymorphisms with population allele frequency of >1%) are not reported.  Although this test may identify some low prevalence germline alterations, this is a tumor-only NGS assay which is designed to detect recurrent somatic mutations associated with myeloid disorders.  If a possible pathogenic germline (inherited) mutation is suspected, then separate clinical germline testing and counseling by a board certified genetic counselor is recommended. 

Weill Cornell Medicine Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464 Fax: (212) 746-8192